Search

Your search keyword '"Mackay, Alan"' showing total 1,085 results

Search Constraints

Start Over You searched for: Author "Mackay, Alan" Remove constraint Author: "Mackay, Alan"
1,085 results on '"Mackay, Alan"'

Search Results

1. GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant

2. Inhibition of exosome biogenesis affects cell motility in heterogeneous sub-populations of paediatric-type diffuse high-grade gliomas

3. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

4. Automated software vulnerability detection with machine learning

5. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs.

6. PATH-23. CLINICOPATHOLOGIC ANALYSIS OF NOVEL METHYLATION CLUSTERS OF IDH-WILDTYPE DIFFUSE GLIOMAS

7. Germline-driven replication repair-deficient high-grade gliomas exhibit unique hypomethylation patterns

8. Beyond crystals: the dialectic of materials and information

9. Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

10. HGG-17. SINGLE-CELL AND SPATIAL ANALYSES DECIPHER THE UNIQUE INVASIVE GROWTH PATTERN OF GLIOMATOSIS CEREBRI

12. Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity

13. Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers

14. Molecular response to aromatase inhibitor treatment in primary breast cancer

15. Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data

18. The Lab

19. Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells

20. Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

21. Supplementary Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

22. Abstract 234: ITCC-P4: Genomic profiling and analyses of pediatric patient tumor and patient-derived xenograft (PDX) models for high throughput in vivo testing

23. Data from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

24. Supplementary Table 3 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

25. Supplementary Table 2 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

26. Data from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

27. Supplementary Data from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

28. Press Conference from Functional Viability Profiles of Breast Cancer

29. Data from Functional Viability Profiles of Breast Cancer

30. Supplementary Methods from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

31. Supplementary Table S3 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

32. Supplementary Figures 1-8, Tables 1-9 from Functional Viability Profiles of Breast Cancer

33. Supplementary Figures S1-S3 from Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma

34. Data from Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma

35. Supplementary Figure Legends from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

36. Supplementary Table 1 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

37. Supplementary Table 4 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

38. Supplementary Figures 1 - 13 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

39. Table S2 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis

40. Supplementary Figure SF2 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial

42. Supplementary Table ST5 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial

43. Supplementary Data from Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers

44. Supplementary Figure 1 from FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas

45. Supplementary Data from A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas

46. Supplementary Figures 1-2, Supplementary Tables 1-2 from Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer

47. Supplementary Table S3 from A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas

48. Figure S5 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis

49. Supplementary Table Legends from A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas

50. Supplementary Table 2 from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

Catalog

Books, media, physical & digital resources